CN117396520A - 包含两个trail三聚体的超trail分子 - Google Patents

包含两个trail三聚体的超trail分子 Download PDF

Info

Publication number
CN117396520A
CN117396520A CN202280038107.8A CN202280038107A CN117396520A CN 117396520 A CN117396520 A CN 117396520A CN 202280038107 A CN202280038107 A CN 202280038107A CN 117396520 A CN117396520 A CN 117396520A
Authority
CN
China
Prior art keywords
ser
trail
gly
glu
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280038107.8A
Other languages
English (en)
Chinese (zh)
Inventor
钱信果
洪维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Anxinhuaide Biotech Co ltd
Original Assignee
Beijing Anxinhuaide Biotech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Anxinhuaide Biotech Co ltd filed Critical Beijing Anxinhuaide Biotech Co ltd
Publication of CN117396520A publication Critical patent/CN117396520A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Lubricants (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280038107.8A 2021-05-27 2022-05-27 包含两个trail三聚体的超trail分子 Pending CN117396520A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/096498 2021-05-27
CN2021096498 2021-05-27
PCT/CN2022/095472 WO2022247923A1 (en) 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers

Publications (1)

Publication Number Publication Date
CN117396520A true CN117396520A (zh) 2024-01-12

Family

ID=84228436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280038107.8A Pending CN117396520A (zh) 2021-05-27 2022-05-27 包含两个trail三聚体的超trail分子

Country Status (9)

Country Link
US (1) US20240254193A1 (enExample)
EP (1) EP4347665A4 (enExample)
JP (1) JP2024519397A (enExample)
KR (1) KR20240013766A (enExample)
CN (1) CN117396520A (enExample)
AU (1) AU2022280269A1 (enExample)
CA (1) CA3220239A1 (enExample)
IL (1) IL308618A (enExample)
WO (1) WO2022247923A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120475984A (zh) * 2023-01-05 2025-08-12 国家纳米科学中心 Dna-trail复合物及其治疗肿瘤的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
PL3145530T3 (pl) * 2014-04-21 2021-10-18 D&D Pharmatech Inc. Agonisty receptora trail w leczeniu chorób zwłóknieniowych
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
WO2017194442A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
WO2018183671A1 (en) * 2017-03-29 2018-10-04 Tdw Group Protein conjugates

Also Published As

Publication number Publication date
US20240254193A1 (en) 2024-08-01
AU2022280269A1 (en) 2023-11-30
JP2024519397A (ja) 2024-05-10
WO2022247923A1 (en) 2022-12-01
CA3220239A1 (en) 2022-12-01
EP4347665A4 (en) 2025-07-30
EP4347665A1 (en) 2024-04-10
KR20240013766A (ko) 2024-01-30
IL308618A (en) 2024-01-01
AU2022280269A9 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
JP7714710B2 (ja) アルブミン結合ドメイン融合タンパク質
US11578427B2 (en) Designed ankyrin repeat domains with altered surface residues
US20240101641A1 (en) Tgf-b-receptor ectodomain fusion molecules and uses thereof
KR102825098B1 (ko) 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디
US10206980B2 (en) IL-15 heterodimeric protein and uses thereof
EP4272838A2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
US20050106674A1 (en) Ligands for EPH-like receptors
HK1248137A1 (zh) 用於治疗癌症的聚乙二醇化白细胞介素-10
US20180346549A1 (en) Method and Compositions for Producing Disulfide-Linked Trimeric TNF Family of Cytokines and Their Use
US20230331858A1 (en) Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
WO2021081193A1 (en) Methods of administration of if-2 receptor agonists
CN116887850A (zh) 双功能性线融合胶原定位的免疫调节分子及其制备方法
EP2221314B1 (en) A soluble tumor necrosis factor receptor mutant
WO2022247923A1 (en) A super-trail molecule comprising two trail trimers
US10618970B2 (en) Method of treating cancer with IL-10 and antibodies that induce ADCC
KR20240118207A (ko) Sirp1a - 및 cd40l-기반 키메라 단백질
HK40101761A (zh) 包含两个trail三聚体的超trail分子
CN102470157A (zh) 广谱erbb配体结合分子及其制备和使用方法
Lee et al. High-yield production of recombinant CLCF1 protein fused with human serum albumin in animal cells and toxicity evaluation in rodents
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
CN108601819B (zh) 用死亡受体激动剂改善系统性硬化症
WO2026003203A1 (en) Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
HK1258208B (en) Ameliorating systemic sclerosis with death receptor agonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101761

Country of ref document: HK

SE01 Entry into force of request for substantive examination